CHEMOCENTRYX, INC. (NASDAQ:CCXI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July27, 2017, Dr.Petrus Bekker notified ChemoCentryx, Inc. (the “Company”) of his retirement as the Company’s Chief Medical Officer, effective July31, 2017, for family medical reasons. Dr.Bekker is retiring to care for a family member and will continue to serve as a consultant to the Company.
The Company expects to enter into a consulting agreement with Dr.Bekker to which Dr.Bekker is expected to serve as a consultant to the Company through at least August1, 2018 and will receive benefits continuation as well as continued vesting of his outstanding unvested restricted stock units.
About CHEMOCENTRYX, INC. (NASDAQ:CCXI)
ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company’s pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.
